Results 141 to 150 of about 45,592 (164)

IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer. [PDF]

Mol Cancer
Ibusuki R, Iwama E, Shimauchi A, Kawano H, Mizusaki S, Nakamura S, Miyazaki Y, Inutsuka Y, Hashisako M, Harada T, Tsuchiya-Kawano Y, Tsutsumi H, Nakanishi T, Nakagaki N, Koga Y, Kimura S, Mashimoto S, Shibahara D, Otsubo K, Yoneshima Y, Tanaka K, Oda Y, Okamoto I.   +22 more
europepmc   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Crizotinib-induced hyperlipidemia in advanced lung adenocarcinoma: A case report and literature review. [PDF]

Medicine (Baltimore)
Ren S, Chen R.
europepmc   +1 more source

DNA methyltransferase inhibitors in hematological malignancies and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 433-461, 15 January 2026.
Abstract Epigenetic modifications such as DNA methylation play a fundamental role in oncogenesis and the progression of neoplasms neoplasias. DNA methyltransferase inhibitors (DNMTi) constitute a family of therapeutic agents that impede the methylation at the 5‐position on cytosine nucleotides, thereby modulating the epigenetic regulation of tumor ...
Valentin Wenger, Guillermo Garcia‐Manero, Robert Zeiser, Michael Lübbert   +3 more
wiley   +1 more source

PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLC. [PDF]

J Biomed Sci
Hsu CC, Huang DD, Hsu WH, Hsieh MS, Lin FY, Tai PC, Chou SY, Tsai HH, Tseng CY, Liao BC, Shih JY, Yang JC.   +11 more
europepmc   +1 more source

Multi‐Omic Profiling of T Cell‐Mediated Rejection After Kidney Transplantation Reveals B Cell Receptor Repertoire Expansion and Its Prognostic Relevance

The FASEB Journal, Volume 40, Issue 1, 15 January 2026.
This study integrates bulk and single‐cell RNA‐seq data to reveal significant B cell receptor (BCR) repertoire expansion, especially IgG isotype amplification, in T cell‐mediated rejection (TCMR) after kidney transplantation. Multi‐omic integration identifies plasma cells as the main BCR carriers in graft tissue and MEI1 as a key regulator promoting ...
He Zhang, Di Zhang, Yuhong Hu, Hao Zhang, Zijian Zhang, Xiaopeng Hu   +5 more
wiley   +1 more source

MICA-129 Met/Met contributes to the susceptibility of colorectal cancer. [PDF]

Medicine (Baltimore)
Ye J, Chang R, Zhang J, Qian F, Ding W.
europepmc   +1 more source

HOXB4 Promotes Bladder Cancer Progression in Part Through Transcriptional Activation of Smoothened

The FASEB Journal, Volume 40, Issue 1, 15 January 2026.
HOXB4 is overexpressed in bladder cancer and associated with poor prognosis. By transcriptionally activating Smoothened (SMO), HOXB4 amplifies SMO–GLI signaling to promote tumor growth and metastatic behavior. This graphical abstract highlights the HOXB4–SMO axis as a key driver of bladder cancer progression and a potential target for future ...
Zhaoheng Jin, Wenjie Yang, Yueqiang Peng, Lin Ma, Ziyi Li, Jie Dong, Zhigang Ji   +6 more
wiley   +1 more source

Inhibition of GALNT7 suppresses cell proliferation and invasiveness while elevating cell apoptosis via the inactivation of the AKT pathway in non-small cell lung cancer. [PDF]

BMJ Open Respir Res
Zhou Y, Shi Y, Zhou J, Zhu X, Wei Z, Zhang Y.   +5 more
europepmc   +1 more source

Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances. [PDF]

Cancers (Basel)
Deng F, Ma W, Wei S.
europepmc   +1 more source